微创机器人-B（02252）今日盘中大涨5.04%，引起投资者广泛关注。这家专注于手术机器人研发和生产的公司发布了令市场振奋的2025年中期业绩报告。
根据公司公告，截至2025年6月30日的六个月内，微创机器人-B实现收入1.76亿元人民币，同比增长77%。公司权益股东应占亏损收窄至1.13亿元人民币，较去年同期的2.77亿元大幅改善。值得注意的是，公司经调整净亏损为9710.8万元人民币，同比减少55.5%，显示出经营状况的显著改善。
业绩改善主要得益于公司多个产品商业化的快速拓展，尤其是海外市场表现亮眼，收入同比大幅增长189%。公司核心产品图迈腔镜手术机器人保持强劲增长势头，鸿鹄骨科手术机器人在国内外市场快速渗透，而血管介入手术机器人R-ONE上市后也获得市场认可。这些因素共同推动了公司整体业务的增长，使投资者对其未来发展前景保持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.